What is the share price of SMS Pharmaceuticals Ltd (SMSPHARMA) today?
The share price of SMSPHARMA as on 27th March 2025 is ₹214.95. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The past returns of SMS Pharmaceuticals Ltd (SMSPHARMA) share are- Past 1 week: 14.20%
- Past 1 month: 7.17%
- Past 3 months: -8.73%
- Past 6 months: -40.60%
- Past 1 year: 14.09%
- Past 3 years: 102.27%
- Past 5 years: 704.05%
What are the peers or stocks similar to SMS Pharmaceuticals Ltd (SMSPHARMA)?
The peers or stocks similar to SMS Pharmaceuticals Ltd (SMSPHARMA) include:What is the dividend yield % of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The current dividend yield of SMS Pharmaceuticals Ltd (SMSPHARMA) is 0.19.What is the market cap of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹1783.28 Cr as of 27th March 2025.What is the 52 week high and low of SMS Pharmaceuticals Ltd (SMSPHARMA) share?
The 52-week high of SMS Pharmaceuticals Ltd (SMSPHARMA) is ₹398 and the 52-week low is ₹175.25.What is the PE and PB ratio of SMS Pharmaceuticals Ltd (SMSPHARMA) stock?
The P/E (price-to-earnings) ratio of SMS Pharmaceuticals Ltd (SMSPHARMA) is 35.79. The P/B (price-to-book) ratio is 3.32.Which sector does SMS Pharmaceuticals Ltd (SMSPHARMA) belong to?
SMS Pharmaceuticals Ltd (SMSPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy SMS Pharmaceuticals Ltd (SMSPHARMA) shares?
You can directly buy SMS Pharmaceuticals Ltd (SMSPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
SMS Pharmaceuticals Ltd
SMSPHARMA Share Price
214.952.04% (+4.29)
SMSPHARMA Share Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SMSPHARMA Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
SMSPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 26.99 | 3.32 | 0.19% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.27 | 6.30 | 0.54% |
SMSPHARMA Analyst Ratings & Forecast
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SMSPHARMA Company Profile
SMS Pharmaceuticals Limited is engaged in manufacturing and sale of bulk drugs and active pharmaceutical ingredients (APIs), and their intermediates.
Investor Presentation
View olderSMSPHARMA Similar Stocks (Peers)
Compare with peersSUNPHARMA
PE Ratio
44.07
1Y Return
10.07%
Buy Reco %
88.24
CIPLA
PE Ratio
28.93
1Y Return
0.27%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
65.78
1Y Return
25.23%
Buy Reco %
68.00
MANKIND
PE Ratio
51.84
1Y Return
6.81%
Buy Reco %
80.00
DRREDDY
PE Ratio
17.40
1Y Return
5.08%
Buy Reco %
45.16
SMSPHARMA Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SMSPHARMA Stock Summary · November 2024
In Q2 FY25, the company achieved an 18% year-on-year revenue increase, driven by strong demand in the ARV and anti-inflammatory segments, despite facing a decline in gross margins to 30% due to rising raw material costs and pricing pressures. Geopolitical uncertainties have prompted a strategic shift towards backward integration, aimed at enhancing profitability and reducing reliance on external suppliers. The ongoing capital expenditure plan focuses on operational efficiency and product validation, with expectations of a 15% to 20% topline growth for FY26. As the company expands its global presence through certifications and capacity enhancements, it remains committed to delivering value while navigating a competitive landscape.
Key Points on SMSPHARMA Stock Performance
SMSPHARMA Stock Growth Drivers
6Strong Revenue Growth
In Q2 FY25, the company reported an 18% year-on-year increase in revenues from operations, totaling
Improved Profitability Metrics
The company reported an EBITDA margin of 16% and a PAT of Rs. 14.1 crores
SMSPHARMA Stock Challenges
4Declining Gross Margins
The company reported a gross margin of 30% for Q2 FY25, which reflects a decline
Pricing Pressures and Erosion
The company has faced significant pricing pressures over the last 3-5 years, resulting in an
SMSPHARMA Forecasts
Price
Revenue
Earnings
SMSPHARMA Share Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeSMSPHARMA Company Revenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeSMSPHARMA Stock EPS (Earnings Per Share) Forecast
Hmm, looks like data is unavailable here. Please come back after some timeSMSPHARMA
Income
Balance Sheet
Cash Flow
Annual Normal View
SMSPHARMA Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 615.01 | 439.58 | 465.07 | 468.31 | 417.06 | 566.62 | 525.07 | 526.96 | 713.73 | 786.79 | ||||||||||
Raw Materials | 399.45 | 325.03 | 294.32 | 307.19 | 259.50 | 313.27 | 387.95 | 299.72 | 425.26 | 648.54 | ||||||||||
| Power & Fuel Cost | 33.81 | 18.23 | 22.57 | 21.75 | 18.99 | 23.31 | 32.58 | 35.97 | 47.12 | |||||||||||
| Employee Cost | 38.11 | 26.92 | 32.80 | 35.59 | 39.35 | 41.17 | 51.02 | 50.08 | 56.78 | |||||||||||
| Selling & Administrative Expenses | 25.23 | 10.23 | 9.67 | 9.84 | 10.18 | 19.02 | 21.12 | 25.28 | 35.68 | |||||||||||
| Operating & Other expenses | 25.59 | -17.42 | 9.97 | 0.40 | 3.90 | 45.27 | -87.41 | 56.46 | 27.66 | |||||||||||
EBITDA | 92.82 | 76.59 | 95.74 | 93.54 | 85.14 | 124.58 | 119.81 | 59.45 | 121.23 | 138.25 | ||||||||||
| Depreciation/Amortization | 19.43 | 19.18 | 19.90 | 19.27 | 22.07 | 22.28 | 32.15 | 32.13 | 31.52 | 33.62 | ||||||||||
| PBIT | 73.39 | 57.41 | 75.84 | 74.27 | 63.07 | 102.30 | 87.66 | 27.32 | 89.71 | 104.63 | ||||||||||
| Interest & Other Items | 17.11 | 15.82 | 15.48 | 11.92 | 12.32 | 11.19 | 19.16 | 21.97 | 23.60 | 19.09 | ||||||||||
| PBT | 56.28 | 41.59 | 60.36 | 62.35 | 50.75 | 91.11 | 68.50 | 5.35 | 66.11 | 85.54 | ||||||||||
| Taxes & Other Items | 15.38 | 13.09 | 28.59 | 22.31 | 19.18 | 28.60 | 6.28 | 12.41 | 16.28 | 19.46 | ||||||||||
| Net Income | 40.90 | 28.50 | 31.77 | 40.04 | 31.57 | 62.51 | 62.22 | -7.06 | 49.83 | 66.08 | ||||||||||
| EPS | 4.83 | 3.37 | 3.75 | 4.73 | 3.73 | 7.38 | 7.35 | -0.83 | 5.89 | 7.81 | ||||||||||
| DPS | 0.20 | 0.20 | 0.25 | 0.25 | 0.25 | 0.30 | 0.30 | 0.30 | 0.40 | 0.40 | ||||||||||
| Payout ratio | 0.04 | 0.06 | 0.07 | 0.05 | 0.07 | 0.04 | 0.04 | — | 0.07 | 0.05 |
SMSPHARMA Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2025
Investor Presentation
Feb 12PDF
Nov 12PDF
SMSPHARMA Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| SMS Pharmaceuticals Ltd | 35.79 | 3.32 | 0.19% |
| Sun Pharmaceutical Industries Ltd | 44.07 | 6.29 | 0.77% |
| Cipla Ltd | 28.93 | 4.45 | 0.88% |
| Torrent Pharmaceuticals Ltd | 65.78 | 15.89 | 0.87% |
SMSPHARMA Stock Price Comparison
Compare SMSPHARMA with any stock or ETFCompare SMSPHARMA with any stock or ETF
SMSPHARMA
SMSPHARMA Shareholdings
SMSPHARMA Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
Lower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
SMSPHARMA Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
SMSPHARMA Shareholding Pattern
SMSPHARMA Shareholding History
Foreign Institutions
Mutual Funds Invested in SMSPHARMA
A list of mutual funds holding the stock, ranked on the basis of Market-cap held which is calculated as the value of stock held in the portfolio divided by its market cap
Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 3 Mutual Funds holding SMS Pharmaceuticals Ltd
| Funds (Top 3) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.6054% | Percentage of the fund’s portfolio invested in the stock 0.13% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 69/99 (-5) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.7122% | Percentage of the fund’s portfolio invested in the stock 3.65% | Change in the portfolio weight of the stock over the last 3 months -0.27% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 20/28 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0005% | Percentage of the fund’s portfolio invested in the stock 0.05% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 90/103 (-1) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing SMSPHARMA stock
Looks like this stock is not in any smallcase yet.
SMSPHARMA Events
SMSPHARMA Dividend Trend
No Dividend Cuts
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SMSPHARMA has increased or maintained dividend levels over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.19%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.90 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SMSPHARMA Upcoming Dividends
No upcoming dividends are available
SMSPHARMA Past Dividends
Cash Dividend
Ex DateEx DateSep 23, 2024
Final
Final | Div/Share: ₹0.40
Dividend/Share
₹0.40
Ex DateEx Date
Sep 23, 2024
Cash Dividend
Ex DateEx DateSep 22, 2023
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2023
Cash Dividend
Ex DateEx DateSep 22, 2022
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2022
Cash Dividend
Ex DateEx DateSep 22, 2021
Final
Final | Div/Share: ₹0.30
Dividend/Share
₹0.30
Ex DateEx Date
Sep 22, 2021
Cash Dividend
Ex DateEx DateMar 26, 2020
Interim
Interim | Div/Share: ₹0.25
Dividend/Share
₹0.25
Ex DateEx Date
Mar 26, 2020
SMSPHARMA Stock News & Opinions
Articles & Videos
Spotlight
SMS Pharma gains after Hyderabad facility completes USFDA inspection
According to an exchange filing, the inspection was conducted from 17 March to 21 March 2025 and concluded with one observation in Form 483. The observation was procedural in nature and does not relate to data integrity or product quality. The company will provide the necessary response to USFDA within the stipulated period. The Hyderabad facility has a manufacturing capacity of 120 KL, specializing in niche small-volume and high-value molecules. It holds multiple regulatory approvals, including USFDA, EU GMP, KFDA, ANVISA, PMDA, and CDSCO. P. Vamsi Krishna, executive director, stated, The successful completion of the USFDA inspection underscores our commitment to quality, compliance, and global regulatory standards. This is the 6th USFDA inspection for this facility, reflecting our team's dedication to maintaining the highest manufacturing practices. This milestone further strengthens our reputation as a trusted partner in the pharmaceutical industry, ensuring an uninterrupted supply of high-quality APIs to key international markets. The official announcement was made on Friday, 21 March 2025, after market hours. SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively. The company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 70 countries. The company's consolidated net profit surged 58.9% to Rs 18.24 crore in Q3 FY25 as against Rs 11.48 crore recorded in Q3 FY24. Revenue from operations rose 7.4% to Rs 173.35 in the quarter ended 31 December 2024. Powered by Capital Market - Live
3 days agoCapital Market - Live
Spotlight
SMS Pharma's Hyderabad facility completes USFDA inspection with 1 observation
According to an exchange filing, the inspection was conducted from 17 March to 21 March 2025 and concluded with one observation in Form 483. The observation was procedural in nature and does not relate to data integrity or product quality. The company will provide the necessary response to USFDA within the stipulated period. The Hyderabad facility has a manufacturing capacity of 120 KL, specializing in niche small-volume and high-value molecules. It holds multiple regulatory approvals, including USFDA, EU GMP, KFDA, ANVISA, PMDA, and CDSCO. P. Vamsi Krishna, executive director, stated, The successful completion of the USFDA inspection underscores our commitment to quality, compliance, and global regulatory standards. This is the 6th USFDA inspection for this facility, reflecting our team's dedication to maintaining the highest manufacturing practices. This milestone further strengthens our reputation as a trusted partner in the pharmaceutical industry, ensuring an uninterrupted supply of high-quality APIs to key international markets. SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively. The company has a proven track record of delivering quality products across a diversified portfolio of therapeutic segments, serving as a trusted partner to a global customer base in over 70 countries. The company's consolidated net profit surged 58.9% to Rs 18.24 crore in Q3 FY25 as against Rs 11.48 crore recorded in Q3 FY24. Revenue from operations rose 7.4% to Rs 173.35 in the quarter ended 31 December 2024. The counter advanced 2.16% to end at Rs 217.90 on the BSE on Friday. Powered by Capital Market - Live
4 days agoCapital Market - Live
Earnings
SMS Pharmaceuticals consolidated net profit rises 58.89% in the December 2024 quarter
Net profit of SMS Pharmaceuticals rose 58.89% to Rs 18.24 crore in the quarter ended December 2024 as against Rs 11.48 crore during the previous quarter ended December 2023. Sales rose 7.35% to Rs 173.35 crore in the quarter ended December 2024 as against Rs 161.48 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales173.35161.48 7 OPM %19.1617.96 - PBDT31.1324.54 27 PBT22.4416.53 36 NP18.2411.48 59 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
SMS Pharmaceuticals schedules board meeting
SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 February 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
SMS Pharmaceuticals consolidated net profit rises 20.20% in the September 2024 quarter
Net profit of SMS Pharmaceuticals rose 20.20% to Rs 14.10 crore in the quarter ended September 2024 as against Rs 11.73 crore during the previous quarter ended September 2023. Sales rose 18.07% to Rs 196.75 crore in the quarter ended September 2024 as against Rs 166.64 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales196.75166.64 18 OPM %15.9916.69 - PBDT28.1623.06 22 PBT19.5415.16 29 NP14.1011.73 20 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
SMS Pharmaceuticals to convene board meeting
SMS Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 8 November 2024Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
SMS Pharmaceuticals to conduct AGM
SMS Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Board of SMS Pharmaceuticals approves incorporation of subsidiary company
The Board of SMS Pharmaceuticals at its meeting held on 05 August 2024 has approved to incorporate a Subsidiary Company in India as a Company for Contract Research Organization (CRO) services on Peptides. Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
SMS Pharmaceuticals fixes record date for dividend
SMS Pharmaceuticals has fixed 23 September 2024 as record date for the purpose of determining the Members eligible to receive dividend for the financial year 2023-24, if approved. Powered by Capital Market - Live
7 months agoCapital Market - Live
SMS Pharmaceuticals consolidated net profit rises 76.45% in the June 2024 quarter
7 months agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of 8.79%, vs industry avg of 9.04%
Over the last 5 years, market share decreased from 0.21% to 0.19%
Over the last 5 years, net income has grown at a yearly rate of 4.47%, vs industry avg of 15.28%